- Home
- PBPB vs ACIU Comparison
PBPB vs ACIU Comparison
Compare PBPB & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PBPB
- ACIU
- Stock Information
- Founded
- PBPB 1977
- ACIU 2003
- Country
- PBPB United States
- ACIU Switzerland
- Employees
- PBPB N/A
- ACIU N/A
- Industry
- PBPB Restaurants
- ACIU Biotechnology: Pharmaceutical Preparations
- Sector
- PBPB Consumer Discretionary
- ACIU Health Care
- Exchange
- PBPB Nasdaq
- ACIU Nasdaq
- Market Cap
- PBPB 278.1M
- ACIU 247.4M
- IPO Year
- PBPB 2013
- ACIU 2016
- Fundamental
- Price
- PBPB $9.48
- ACIU $2.03
- Analyst Decision
- PBPB Strong Buy
- ACIU Strong Buy
- Analyst Count
- PBPB 3
- ACIU 2
- Target Price
- PBPB $15.33
- ACIU $12.00
- AVG Volume (30 Days)
- PBPB 356.9K
- ACIU 199.8K
- Earning Date
- PBPB 03-06-2025
- ACIU 03-13-2025
- Dividend Yield
- PBPB N/A
- ACIU N/A
- EPS Growth
- PBPB 670.59
- ACIU N/A
- EPS
- PBPB 1.31
- ACIU N/A
- Revenue
- PBPB $462,598,000.00
- ACIU $30,136,397.00
- Revenue This Year
- PBPB $5.67
- ACIU $120.91
- Revenue Next Year
- PBPB $3.78
- ACIU $13.82
- P/E Ratio
- PBPB $7.22
- ACIU N/A
- Revenue Growth
- PBPB N/A
- ACIU 84.51
- 52 Week Low
- PBPB $6.28
- ACIU $1.97
- 52 Week High
- PBPB $13.48
- ACIU $4.98
- Technical
- Relative Strength Index (RSI)
- PBPB 39.73
- ACIU 29.25
- Support Level
- PBPB $8.89
- ACIU $2.05
- Resistance Level
- PBPB $9.64
- ACIU $2.33
- Average True Range (ATR)
- PBPB 0.49
- ACIU 0.13
- MACD
- PBPB -0.03
- ACIU -0.02
- Stochastic Oscillator
- PBPB 24.13
- ACIU 5.00
About PBPB Potbelly Corporation
Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.